Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction

Thrombosis Research

Volumn 120, Issue 3, 2007, Pages 361-366

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Garcia Gonzalez, Martín J ^a   Reiter, Russel J ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Day night variation; Matrix metalloproteinase 9; Melatonin; Myocardial infarction

Indexed keywords

GELATINASE B; MELATONIN;

AGED; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CORRELATION COEFFICIENT; FEMALE; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; LIGHT DARK CYCLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE;

AGED; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MELATONIN; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 34249947798     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.10.010     Document Type: Article

References (39)

1. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases; structure, function and biochemistry. Circ Res 92 (2003) 827-839
2. Lu L., Gunja-Smith Z., Woessner J.F., Ursell P.C., Nissen T., Galardy R.E., et al. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol 279 (2000) H601-H609
3. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cadiovasc Res 46 (2000) 214-224
4. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
5. Ferroni P., Basili S., Martini F., Cardarello C.M., Ceci F., Di Franco M., et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 51 (2003) 295-300
6. Jankovic B.D. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci 741 (1994) 1-38
7. Maestroni G.J.M., Conti A., and Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci 521 (1998) 140-148
8. Guerrero J.M., and Reiter R.J. Melatonin-immune system relationship. Curr Top Med Chem 2 (2002) 167-179
9. Reiter R.J. Pineal melatonin. Cell biology of its synthesis and of its physiological interactions. Endocr Rev 12 (1991) 151-180
10. Zaidan R., Geoffriau M., and Brun J. Melatonin able to influence its secretion in humans: description of a phase-response curve. Neuroendocrinology 60 (1994) 105-112
11. Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett 23 (2002) 79-83
12. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M., Ferrer J., de la Rosa A., Vargas M., et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 26 (2004) 89-93
13. Dominguez-Rodriguez A., Garcia-Gonzalez M., Abreu-Gonzalez P., Ferrer J., and Kaski J.C. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 10-12
14. Dominguez-Rodriguez A., Garcia-Gonzalez M., and Abreu-Gonzalez P. Link between arterial inflammation and circadian rhythm: the oversight aspect in the year 2004. J Am Coll Cardiol 47 (2006) 688
15. Van de Werf F., Ardissino D., Betriu A., Cokkinos D.V., Falk E., Fox K.A., et al., Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24 (2003) 28-66
16. Carrillo-Vico A., Guerrero J.M., Lardone P.J., and Reiter R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 27 (2005) 189-200
17. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M.J., Sanchez J., Marrero F., and de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 33 (2002) 248-252
18. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., Ferrer-Hita J., Vargas M., and Reiter R.J. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 180 (2005) 101-105
19. Reiter R.J., and Tan D.X. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 58 (2003) 10-19
20. Kanikowska D., Hirata Y., Hyun K., and Tokura H. Acute phase proteins, body temperature and urinary melatonin under the influence of bright and dim light intensities during the daytime. J Physiol Anthropol Appl Human Sci 20 (2001) 333-338
21. Tayebjee M.H., Lip G.Y., Blann A.D., and MacFadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115 (2005) 205-210
22. Buhimshi I.A., Kramer W.B., Buhimshi C.S., Thompson L.P., and Weiner C.P. Reduction-oxidation (redox) state regulation of matrix metalloproteinase activity in human fetal membranes. Am J Obstet 182 (2000) 458-464
23. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
24. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., and Kamada T. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
25. Beyer C.E., Steketee J.D., and Saphier D. Antioxidant properties of melatonin-an emerging mystery. Biochem Pharmacol 56 (1998) 1265-1272
26. Allegra M., Reiter R.J., Tan D.X., Gentile C., Tesoriere L., and Livrea M.A. The chemistry of melatonin's interaction with reactive species. J Pineal Res 34 (2003) 1-10
27. Reiter R.J., Tan D., Poeggeler B., Menendez-Pelaez A., Chen L.D., and Saarela S. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 719 (1994) 1-12
28. Pieri C., Moroni F., Marra M., Marcheselli F., and Recchioni R. Melatonin is an efficient antioxidant. Arch Gerontol Geriatr 20 (1995) 159-165
29. Wainwright C.L. Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion. Curr Opin Pharmacol 4 (2004) 132-138
30. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98 (1996) 2572-2579
31. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., and Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101 (2000) 1833-1839
32. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103 (2001) 2181-2187
33. Granger D.N. I/R injury: role of leukocyte-endothelial adhesion. News Physiol Sci 12 (1997) 142-143
34. Mori N., Sato H., Hayashibara T., Senba M., Geleziunas R., Wada A., et al. Helicobacter pylori induce matrix metalloproteinase-9 through activation of nuclear factor kappa B. Gastroenterology 124 (2003) 983-992
35. Lezovalc'h F., Szaropani M., and Behl C. N-Acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppresses the activity of the transcription factor NF kappa B activation. FASEB J 12 (1998) 685-693
36. Reiter R.J., Calvo J.R., Karbownik M., Qi W., and Tan D.X. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 917 (2000) 376-386
37. Creemers E.E., Cleutjens J.P., Smits J.F., and Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210
38. Rouy D., Ernens I., Jeanty C., and Wagner D.R. Plasma storage at - 80 °C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338 (2005) 294-298
39. Tziakas D.N., Chalikias G.K., Hatzinikolaou E.I., Stakos D.A., Tentes I.K., Kortsaris A., et al. Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res 118 (2006) 221-227